APA (7th ed.) Citation

O, R., DG, B., J, A., D, B., D, C., C, C., . . . DJ, W. (2026). Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor Immunity. Journal of medicinal chemistry. https://doi.org/10.1021/acs.jmedchem.6c00683

Chicago Style (17th ed.) Citation

O, Robles, et al. "Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor Immunity." Journal of Medicinal Chemistry 2026. https://doi.org/10.1021/acs.jmedchem.6c00683.

MLA (9th ed.) Citation

O, Robles, et al. "Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor Immunity." Journal of Medicinal Chemistry, 2026, https://doi.org/10.1021/acs.jmedchem.6c00683.